SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Gold/Mining/Energy : Nuvo Research Inc
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: the Chief who wrote (4048)4/7/2000 11:46:00 AM
From: the Chief  Read Replies (1) of 14101
 
This point should have been added to the original post. DMX has "suffered" thru the trials process preserving capital and shareholder value all the way thru the tedium. In the end we will have a company that takes the "elephant" portion of the revenues from all of its drugs, because of its refusal to bend to "large drug producers early buyin on the cheap".

This will ensure a much larger profit margin than would normally be afforded a "small" biomed. I am consistently heartened by other biomeds that are three years away from "stage 3 trials approval" selling for more than DMX. The reason is simple.....on FDA approval this thing will "pop" far beyond the others market capitalization, reaching my $23.00 interim forecast in a flash, with little to NO pullback from that level.

Obviously "long" on DMX

have a good day

the Chief
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News